News

December 17, 2019December 20, 2019

PharmaMar Asks FDA for Accelerated Approval of Lurbinectedin to Treat Relapsed SCLC

News

PharmaMar is asking the U.S. Food and Drug Administration (FDA) to approve lurbinectedin (PM1183) to treat those with small cell lung cancer (SCLC) whose disease progressed following platinum-based chemotherapy. The new ... Read more

December 13, 2019

Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis

News

Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 clinical ... Read more

December 12, 2019January 6, 2020

Gut Bacteria as Means of Boosting Immunotherapy in Advanced Cancers Focus of Clinical Trial

News

Vedanta Bioscience has started a Phase 1/2 trial to test its investigational oral microbiome therapy, VE800, in combination with the immune checkpoint inhibitor Opdivo (nivolumab) as treatment for certain advanced cancers. VE800 ... Read more

December 11, 2019

Single-Blinded Trial Design Prevents Patients From Withdrawing Prematurely, Analysis Shows

News

BeyondSpring’s single-blinded trial design, in which patients are unaware of the treatment they receive, effectively prevented participants from prematurely withdrawing from the company’s DUBLIN-3 study due to dissatisfaction with their ... Read more

December 9, 2019

FDA Grants N-803 Combo Breakthrough Therapy Status for Non-Muscle Invasive Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ImmunityBio‘s interleukin-15 (IL-15) agonist N-803, in combination with Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive ... Read more

December 5, 2019December 6, 2019

Tecentriq-chemo Combo OK’d as First-line Treatment for Certain Metastatic NSCLC Patients

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy — Abraxane (nab-paclitaxel) plus carboplatin — as a first-line treatment for patients with metastatic non-squamous non-small ... Read more

December 4, 2019

Bavencio First-line Maintenance Failed to Extend Survival in Patients with Advanced Gastric and GEJ Cancer

News

First-line maintenance therapy with Bavencio (avelumab) failed to extend the overall survival of patients with advanced stomach or gastroesophageal junction (GEJ) cancer, as compared to standard care, according to the ... Read more

November 27, 2019November 27, 2019

Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers

News

Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. The ... Read more

November 15, 2019December 5, 2019

Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial

News

Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according to ... Read more

November 13, 2019

CytomX Initiates Phase 2 Trial Testing CX-072, Yervoy Combo in Relapsed or Refractory Melanoma

News

CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating people ... Read more